#BEGIN_DRUGCARD DB02595

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
92953-54-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C16H30N3O14S2

# Chemical_IUPAC_Name:
(2S,3S,5R)-3-{[(2R,3S,4S,5R,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-2-(hydroxymethyl)-5-[(2-sulfoethyl)carbamoyl]pyrrolidin-1-ium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Bulgecin A

# HET_ID:
BLG

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C16H29N3O14S2/c1-7(22)18-12-13(23)14(33-35(28,29)30)11(6-21)32-16(12)31-10-4-8(19-9(10)5-20)15(24)17-2-3-34(25,26)27/h8-14,16,19-21,23H,2-6H2,1H3,(H,17,24)(H,18,22)(H,25,26,27)(H,28,29,30)/p+1/t8-,9+,10+,11-,12+,13+,14+,16-/m1/s1

# InChI_Key:
InChIKey=RPNZWZDLNYCCIG-RWQOYFMZSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2595

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
552.551

# Molecular_Weight_Mono:
552.116919063

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1D0L

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
-2

# Predicted_Water_Solubility:
5.61e+00 g/l

# Primary_Accession_No:
DB02595

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936433

# PubChem_Substance_ID:
46507352

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00715

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)[C@@H](OS(O)(=O)=O)[C@@H](CO)O[C@H]1O[C@H]1C[C@@H]([NH2+][C@H]1CO)C(=O)NCCS(O)(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:17 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Periplasm. Note=Tightly associated with the murein sacculus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M69185

# Drug_Target_1_GenBank_ID_Protein:
147836

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
slt

# Drug_Target_1_Gene_Sequence:
>1938 bp
GTGGAAAAAGCCAAACAAGTTACCTGGCGGCTGTTGGCTGCCGGTGTCTGTCTGCTGACG
GTCAGCAGCGTGGCGCGAGCCGACTCACTGGATGAGCAGCGTAGTCGTTACGCGCAAATC
AAGCAGGCCTGGGATAATCGACAAATGGATGTGGTCGAACAAATGATGCCTGGACTGAAG
GATTATCCGCTTTATCCCTACCTGGAATACCGCCAGATCACCGATGATCTGATGAATCAA
CCGGCGGTGACGGTCACTAACTTTGTTCGCGCTAACCCCACGCTTCCTCCCGCTCGCACG
CTGCAATCTCGTTTCGTCAATGAACTGGCGCGGCGTGAAGACTGGCGTGGCTTGTTAGCC
TTTAGCCCGGAAAAGCCCGGAACTACCGAAGCGCAATGTAATTACTACTATGCGAAATGG
AACACCGGGCAGAGTGAAGAAGCCTGGCAAGGGGCGAAAGAGCTGTGGCTAACCGGCAAG
AGCCAGCCTAACGCCTGTGACAAGTTATTTAGCGTCTGGCGTGCGTCAGGTAAACAAGAT
CCGCTGGCGTATTTAGAGCGTATCCGTCTGGCGATGAAAGCGGGTAACACAGGCCTGGTA
ACAGTGCTGGCAGGGCAGATGCCTGCCGATTACCAGACTATCGCCTCGGCAATCATTTCA
CTGGCGAACAACCCTAATACGGTACTGACCTTCGCGCGTACAACTGGCGCGACCGATTTT
ACCCGTCAAATGGCGGCGGTGGCGTTTGCCAGTGTGGCGCGGCAGGATGCTGAGAATGCA
CGGCTGATGATCCCATCGCTTGCCCAGGCGCAGCAGCTTAATGAAGATCAGATTCAGGAG
CTGCGCGATATCGTCGCCTGGCGTTTGATGGGCAACGATGTCACCGACGAGCAGGCGAAA
TGGCGCGATGACGCCATTATGCGCTCGCAATCTACTTCGCTTATTGAACGCCGTGTACGA
ATGGCGCTTGGCACCGGCGATCGTCGCGGCCTGAATACCTGGCTGGCGCGTCTGCCTATG
GAAGCGAAAGAGAAAGATGAATGGCGTTACTGGCAGGCGGATTTATTGCTGGAACGCGGA
CGTGAAGCTGAAGCAAAAGAGATTTTGCATCAACTCATGCAACAGCGTGGTTTCTACCCG
ATGGTTGCAGCACAACGCATCGGCGAAGAGTATGAGCTGAAGATTGATAAAGCGCCGCAG
AATGTTGACAGCGCCCTGACTCAGGGGCCGGAGATGGCGCGCGTGCGCGAGTTGATGTAC
TGGAATCTCGATAATACCGCGCGTAGCGAGTGGGCCAATCTGGTGAAGAGCAAGTCAAAA
ACAGAGCAGGCTCAACTGGCGCGGTATGCTTTCAACAACCAATGGTGGGATCTTAGCGTT
CAGGCAACGATCGCCGGGAAGCTGTGGGATCATCTGGAAGAGCGATTCCCGCTGGCTTAC
AACGATCTTTTCAAACGCTACACCAGCGGTAAGGAGATCCCGCAAAGCTATGCGATGGCG
ATTGCTCGTCAGGAGAGCGCCTGGAATCCGAAAGTGAAATCACCGGTAGGGGCCAGCGGC
TTGATGCAGATTATGCCTGGTACAGCGACCCATACGGTGAAGATGTTCTCTATTCCCGGT
TATAGCAGTCCTGGGCAATTGCTGGATCCGGAAACGAATATCAACATTGGCACCAGTTAC
CTGCAATATGTTTATCAGCAGTTTGGCAATAATCGTATTTTCTCCTCAGCAGCTTATAAC
GCCGGACTAGGGCGGGTGCGAACCTGGCTTGGCAACAGCGCCGGGCGTATCGACGCAGTG
GCATTTGTCGAGAGTATTCCATTCTCCGAGACGCGCGGTTATGTGAAGAACGTGCTGGCT
TATGACGCTTACTACCGCTATTTCATGGGGGATAAACCGACGTTGATGAGCGCCACGGAA
TGGGGACGTCGTTACTGA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
10452894	van Asselt EJ, Thunnissen AM, Dijkstra BW: High resolution crystal structures of the Escherichia coli lytic transglycosylase Slt70 and its complex with a peptidoglycan fragment. J Mol Biol. 1999 Aug 27;291(4):877-98.
1938883	Engel H, Kazemier B, Keck W: Murein-metabolizing enzymes from Escherichia coli: sequence analysis and controlled overexpression of the slt gene, which encodes the soluble lytic transglycosylase. J Bacteriol. 1991 Nov;173(21):6773-82.
2184239	Rozeboom HJ, Dijkstra BW, Engel H, Keck W: Crystallization of the soluble lytic transglycosylase from Escherichia coli K12. J Mol Biol. 1990 Apr 20;212(4):557-9.
2695826	Betzner AS, Keck W: Molecular cloning, overexpression and mapping of the slt gene encoding the soluble lytic transglycosylase of Escherichia coli. Mol Gen Genet. 1989 Nov;219(3):489-91.
7001368	Singleton CK, Roeder WD, Bogosian G, Somerville RL, Weith HL: DNA sequence of the E. coli trpR gene and prediction of the amino acid sequence of Trp repressor. Nucleic Acids Res. 1980 Apr 11;8(7):1551-60.
7012834	Gunsalus RP, Yanofsky C: Nucleotide sequence and expression of Escherichia coli trpR, the structural gene for the trp aporepressor. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7117-21.
7548026	Thunnissen AM, Rozeboom HJ, Kalk KH, Dijkstra BW: Structure of the 70-kDa soluble lytic transglycosylase complexed with bulgecin A. Implications for the enzymatic mechanism. Biochemistry. 1995 Oct 3;34(39):12729-37.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
8107871	Thunnissen AM, Dijkstra AJ, Kalk KH, Rozeboom HJ, Engel H, Keck W, Dijkstra BW: Doughnut-shaped structure of a bacterial muramidase revealed by X-ray crystallography. Nature. 1994 Feb 24;367(6465):750-3.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3691

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
73354

# Drug_Target_1_Name:
Soluble lytic murein transglycosylase precursor

# Drug_Target_1_Number_of_Residues:
645

# Drug_Target_1_PDB_ID:
1QSA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01464	SLT

# Drug_Target_1_Protein_Sequence:
>Soluble lytic murein transglycosylase precursor
MEKAKQVTWRLLAAGVCLLTVSSVARADSLDEQRSRYAQIKQAWDNRQMDVVEQMMPGLK
DYPLYPYLEYRQITDDLMNQPAVTVTNFVRANPTLPPARTLQSRFVNELARREDWRGLLA
FSPEKPGTTEAQCNYYYAKWNTGQSEEAWQGAKELWLTGKSQPNACDKLFSVWRASGKQD
PLAYLERIRLAMKAGNTGLVTVLAGQMPADYQTIASAIISLANNPNTVLTFARTTGATDF
TRQMAAVAFASVARQDAENARLMIPSLAQAQQLNEDQIQELRDIVAWRLMGNDVTDEQAK
WRDDAIMRSQSTSLIERRVRMALGTGDRRGLNTWLARLPMEAKEKDEWRYWQADLLLERG
REAEAKEILHQLMQQRGFYPMVAAQRIGEEYELKIDKAPQNVDSALTQGPEMARVRELMY
WNLDNTARSEWANLVKSKSKTEQAQLARYAFNNQWWDLSVQATIAGKLWDHLEERFPLAY
NDLFKRYTSGKEIPQSYAMAIARQESAWNPKVKSPVGASGLMQIMPGTATHTVKMFSIPG
YSSPGQLLDPETNINIGTSYLQYVYQQFGNNRIFSSAAYNAGPGRVRTWLGNSAGRIDAV
AFVESIPFSETRGYVKNVLAYDAYYRYFMGDKPTLMSATEWGRRY

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
Murein-degrading enzyme. Catalyzes the cleavage of the glycosidic bonds between N-acetylmuramic acid and N- acetylglucosamine residues in peptidoglycan. May play a role in recycling of muropeptides during cell elongation and/or cell division

# Drug_Target_1_SwissProt_ID:
P0AGC3

# Drug_Target_1_SwissProt_Name:
SLT_ECOLI

# Drug_Target_1_Synonyms:
EC 3.2.1.-
Exomuramidase
Slt70

# Drug_Target_1_Theoretical_pI:
9.06

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cell outer membrane
lipid-anchor
periplasmic side

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U18785

# Drug_Target_2_GenBank_ID_Protein:
642538

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
mltB

# Drug_Target_2_Gene_Sequence:
>1086 bp
ATGTTCAAGCGTCGTTATGTAACATTGCTTCCCCTTTTTGTGTTGCTTGCCGCCTGTAGC
AGCAAGCCAAAACCTACTGAGACTGATACGACCACCGGAACGCCGTCTGGCGGCTTCCTG
CTTGAGCCGCAGCACAATGTGATGCAGATGGGCGGCGATTTCGCTAATAACCCGAATGCC
CAGCAGTTCATCGACAAAATGGTGAACAAACACGGTTTCGATCGTCAGCAGTTGCAGGAA
ATTCTCTCTCAGGCGAAGCGTCTGGATTCGGTACTGCGGCTGATGGATAACCAGGCACCA
ACCACATCGGTGAAACCCCCATCAGGTCCGAACGGCGCATGGCTCCGTTATCGCAAAAAA
TTTATTACGCCGGACAACGTGCAGAACGGTGTGGTTTTCTGGAATCAGTATGAAGATGCG
TTGAATCGCGCGTGGCAGGTGTATGGAGTACCGCCGGAAATTATCGTCGGGATTATCGGC
GTTGAAACCCGCTGGGGGCGCGTGATGGGGAAAACTCGCATCCTCGATGCGCTGGCAACG
CTGTCATTTAACTACCCACGCCGCGCGGAGTATTTCTCTGGCGAGCTGGAAACCTTCCTG
TTGATGGCGCGCGACGAGCAGGACGATCCGCTCAATCTGAAAGGTTCCTTTGCCGGGGCG
ATGGGCTACGGACAGTTTATGCCGTCGTCTTACAAACAATATGCGGTAGATTTCAGCGGC
GACGGGCATATCAACCTGTGGGATCCGGTTGATGCGATCGGTAGCGTGGCGAACTATTTC
AAAGCGCACGGCTGGGTGAAAGGCGATCAGGTCGCGGTAATGGCAAACGGTCAGGCTCCA
GGCTTGCCAAATGGCTTCAAAACTAAGTACAGCATTTCGCAGCTTGCCGCCGCAGGTTTA
ACGCCACAGCAGCCGCTGGGCAACCATCAACAAGCCAGCCTGCTGCGTCTGGATGTTGGC
ACCGGCTACCAGTACTGGTACGGTCTGCCGAACTTCTACACCATCACCCGTTACAACCAC
AGCACCCATTACGCAATGGCGGTCTGGCAGTTAGGACAAGCCGTGGCGCTGGCGCGAGTA
CAGTAG

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
10545329	van Asselt EJ, Dijkstra AJ, Kalk KH, Takacs B, Keck W, Dijkstra BW: Crystal structure of Escherichia coli lytic transglycosylase Slt35 reveals a lysozyme-like catalytic domain with an EF-hand. Structure. 1999 Oct 15;7(10):1167-80.
10570954	van Asselt EJ, Dijkstra BW: Binding of calcium in the EF-hand of Escherichia coli lytic transglycosylase Slt35 is important for stability. FEBS Lett. 1999 Sep 24;458(3):429-35.
10684641	van Asselt EJ, Kalk KH, Dijkstra BW: Crystallographic studies of the interactions of Escherichia coli lytic transglycosylase Slt35 with peptidoglycan. Biochemistry. 2000 Feb 29;39(8):1924-34.
3553176	Yamada M, Saier MH Jr: Glucitol-specific enzymes of the phosphotransferase system in Escherichia coli. Nucleotide sequence of the gut operon. J Biol Chem. 1987 Apr 25;262(12):5455-63.
7476170	Ehlert K, Holtje JV, Templin MF: Cloning and expression of a murein hydrolase lipoprotein from Escherichia coli. Mol Microbiol. 1995 May;16(4):761-8.
7789526	Dijkstra AJ, Hermann F, Keck W: Cloning and controlled overexpression of the gene encoding the 35 kDa soluble lytic transglycosylase from Escherichia coli. FEBS Lett. 1995 Jun 12;366(2-3):115-8.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9761817	Van Asselt EJ, Perrakis A, Kalk KH, Lamzin VS, Dijkstra BW: Accelerated X-ray structure elucidation of a 36 kDa muramidase/transglycosylase using wARP. Acta Crystallogr D Biol Crystallogr. 1998 Jan 1;54(Pt 1):58-73.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2876

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
40256

# Drug_Target_2_Name:
Membrane-bound lytic murein transglycosylase B

# Drug_Target_2_Number_of_Residues:
361

# Drug_Target_2_PDB_ID:
1D0L

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
>Membrane-bound lytic murein transglycosylase B precursor
MFKRRYVTLLPLFVLLAACSSKPKPTETDTTTGTPSGGFLLEPQHNVMQMGGDFANNPNA
QQFIDKMVNKHGFDRQQLQEILSQAKRLDSVLRLMDNQAPTTSVKPPSGPNGAWLRYRKK
FITPDNVQNGVVFWNQYEDALNRAWQVYGVPPEIIVGIIGVETRWGRVMGKTRILDALAT
LSFNYPRRAEYFSGELETFLLMARDEQDDPLNLKGSFAGAMGYGQFMPSSYKQYAVDFSG
DGHINLWDPVDAIGSVANYFKAHGWVKGDQVAVMANGQAPGLPNGFKTKYSISQLAAAGL
TPQQPLGNHQQASLLRLDVGTGYQYWYGLPNFYTITRYNHSTHYAMAVWQLGQAVALARV
Q

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-18

# Drug_Target_2_Specific_Function:
Murein-degrading enzyme. Catalyzes the cleavage of the glycosidic bonds between N-acetylmuramic acid and N- acetylglucosamine residues in peptidoglycan. May play a role in recycling of muropeptides during cell elongation and/or cell division

# Drug_Target_2_SwissProt_ID:
P41052

# Drug_Target_2_SwissProt_Name:
MLTB_ECOLI

# Drug_Target_2_Synonyms:
35 kDa soluble lytic transglycosylase
EC 3.2.1.-
Membrane-bound lytic murein transglycosylase B precursor
Murein hydrolase B
Slt35

# Drug_Target_2_Theoretical_pI:
9.37

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB02595
